TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS

Transthyretin Amyloidosis Treatment MarketSize and Trends

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Figure 1. Global Transthyretin Amyloidosis Treatment Market Share (%), by Drug Type, 2018 and 2026

Robust pipeline of transthyretin amyloidosis treatment drugs is expected to boost the market growth over the forecast period

Major players in the market have novel drugs in the pipeline, which are in late-stage clinical trials and are expected to receive approval in the near future. For instance, Eidos Therapeutics, Inc. is developing AG10— an orally-administered, small molecule designed to potently and selectively stabilize tetrameric TTR, thereby interfering with events that give rise to ATTR. The drug is currently in Phase 2 clinical trial.

Akcea Therapeutics Inc. is co-developing AKCEA-TTR- LRx with Ionis Pharmaceuticals to inhibit the production of transthyretin. Akcea Therapeutics Inc. is focused on developing AKCEA-TTR-LRx for patients with both hereditary and wild type form of the disease. AKCEA-TTR-LRx is planning to enter clinical development in 2018.                     

Figure 2. Global Transthyretin Amyloidosis Treatment Market Share (%), by Disease Type, 2018 and 2026

Source: Coherent Market Insights Analysis (2017)